Skip to main content
SpringerLink
Log in
Book cover

Psychiatric Nonadherence pp 17–30Cite as

Nonadherence in Childhood Disorders: Attention-Deficit/Hyperactivity Disorder

  • Chapter
  • First Online:

Abstract

Despite effective treatments for attention-deficit/hyperactivity disorder to significantly ameliorate symptoms and improve quality of life for patients and families, treatment adherence and continuity are frequently inadequate to yield satisfactory outcomes. This chapter describes attention-deficit/hyperactivity disorder, its course, and features of its optimal treatment; reviews data on pharmacotherapy adherence; and discusses factors influencing treatment adherence, including those pertaining to the medication regimen, service delivery, patient characteristics, family factors, and developmental issues. Adherence improves when diagnostic evaluations are thorough rather than perfunctory, and with simpler medication regimens, prompt follow-up to adjust treatment and address adverse effects, and ongoing encouragement of communication and concerns by parents and patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Barkley RA. Emotional dysregulation is a core component of ADHD. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 4th ed. New York: Guilford Press; 2015. p. 81–115.

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.

    Google Scholar 

  3. Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21(7):872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhu JL, Olsen J, Liew Z, Li J, Niclasen J, Obel C. Parental smoking during pregnancy and ADHD in children: the Danish National Birth Cohort. Pediatr Dent. 2014;134(2):e382–8.

    Google Scholar 

  5. Sibley MH, Swanson JM, Arnold LE, Hechtman LT, Owens EB, Stehli A, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry. 2017;58(6):655–62.

    Article  PubMed  Google Scholar 

  6. Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996.

    PubMed  Google Scholar 

  8. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–86.

    Article  Google Scholar 

  9. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality, Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatr Dent. 2011;128(5):1007–22.

    Google Scholar 

  10. DiMatteo MR, Haskard-Zolnierek KB, Martin LR. Improving patient adherence: a three-factor model to guide practice. Health Psychol Rev. 2012;6(1):74–91.

    Article  Google Scholar 

  11. Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatr Dent. 2003;112(5):e404.

    Google Scholar 

  13. Vitiello B, Severe JB, Greenhill LL, Arnold E, Abikoff HB, Bukstein O, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40:188–96.

    Article  CAS  PubMed  Google Scholar 

  14. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord. 2007;11(2):157–66.

    Article  PubMed  Google Scholar 

  15. Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother. 2008;8(10):1563–71.

    Article  PubMed  Google Scholar 

  16. Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Mental Health. 2016;21(4):192–200.

    Article  Google Scholar 

  17. Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) – a pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13(50):iii–iv, ix–xi, 1–120.

    PubMed  Google Scholar 

  18. Zetterqvist J, Asherson P, Halldner L, Langstrom N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128(1):70–7.

    Article  CAS  PubMed  Google Scholar 

  19. Lambert MC, Reid R, Prosser B, Bussing R. A survival analysis of psychostimulant prescriptions in New South Wales from 1990 to 2010. J Child Adolesc Psychopharmacol. 2015;25(6):475–81.

    Article  PubMed  Google Scholar 

  20. Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):791–815.

    Article  PubMed  Google Scholar 

  21. Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15(7):371–8. Article no. 371.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009;48(5):501–10.

    Article  PubMed  Google Scholar 

  23. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lawson KA, Johnsrud M, Hodgkins P, Sasane R, Crismon ML. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther. 2012;34(4):944–956.e4.

    Article  PubMed  Google Scholar 

  25. Marcus SC, Durkin M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(5):480–9.

    Article  PubMed  Google Scholar 

  26. Hodgkins P, Sasane R, Christensen L, Harley C, Liu F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin. 2011;27(Suppl 2):53–62.

    Article  CAS  PubMed  Google Scholar 

  27. Lachaine J, Beauchemin C, Sasane R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med. 2012;124(3):139–48.

    Article  PubMed  Google Scholar 

  28. Palli SR, Kamble PS, Chen H, Aparasu RR. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(2):139–48.

    Article  CAS  PubMed  Google Scholar 

  29. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977–89.

    Article  CAS  PubMed  Google Scholar 

  30. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24–31.

    Article  PubMed  Google Scholar 

  31. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60(2):204–11.

    Article  CAS  PubMed  Google Scholar 

  32. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry. 2009;48(1):51–9.

    Article  PubMed  Google Scholar 

  33. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry. 2012;12:219.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572–8.

    Article  PubMed  Google Scholar 

  35. Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, et al. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Psychiatry Clin Neurosci. 2012;66(1):53–63.

    Article  CAS  PubMed  Google Scholar 

  36. Adler LA, Lynch LR, Shaw DM, Wallace SP, Ciranni MA, Briggie AM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011;123(5):71–9.

    Article  PubMed  Google Scholar 

  37. Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22(7):603–11.

    Article  CAS  PubMed  Google Scholar 

  38. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174–87.

    Article  PubMed  Google Scholar 

  39. Wehmeier PM, Dittmann RW, Banaschewski T. Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study. Atten Defic Hyperact Disord. 2015;7(2):165–74.

    Article  PubMed  Google Scholar 

  40. Brinkman WB, Baum R, Kelleher KJ, Peugh J, Gardner W, Lichtenstein P, et al. Relationship between attention-deficit/hyperactivity disorder care and medication continuity. J Am Acad Child Adolesc Psychiatry. 2016;55(4):289–94.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Naenen-Hernani K, Palazon-Bru A, Colomina-Climent F, Gil-Guillen VF, GAIPNA (Alicante Research Group in Child and Adolescent Psychiatry). Influence of written informed consent for methylphenidate on medicine persistence rates in children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2017;38(8):603–10.

    Article  PubMed  Google Scholar 

  42. Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459–68.

    Article  PubMed  Google Scholar 

  43. Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? Clin Pediatr. 2012;51(8):763–9.

    Article  Google Scholar 

  44. Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. Fam Pract. 2018;35(2):142–50.

    Article  PubMed  Google Scholar 

  45. Ahmed R, Borst J, Wei YC, Aslani P. Parents’ perspectives about factors influencing adherence to pharmacotherapy for ADHD. J Atten Disord. 2017;21(2):91–9.

    Article  PubMed  Google Scholar 

  46. Braun S, Russo L, Zeidler J, Linder R, Hodgkins P. Descriptive comparison of drug treatment-persistent, −nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany. [Erratum appears in Clin Ther. 2016 May;38(5):1254–1258; PMID: 27136713]. Clin Ther. 2013;35(5):673–85.

    Article  PubMed  Google Scholar 

  47. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.

    Article  PubMed  Google Scholar 

  48. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46(8):989–1002.

    Article  PubMed  Google Scholar 

  49. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006;16(3):286–97.

    Article  PubMed  Google Scholar 

  50. dosReis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW Jr, Ellwood LC. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2003;24(3):155–62.

    Article  PubMed  Google Scholar 

  51. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol. 2009;19(6):673–81.

    Article  PubMed  Google Scholar 

  52. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed on August 28, 2018.

    Google Scholar 

  53. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.

    Article  CAS  PubMed  Google Scholar 

  54. Leslie LK, Plemmons D, Monn AR, Palinkas LA. Investigating ADHD treatment trajectories: listening to families’ stories about medication use. J Dev Behav Pediatr. 2007;28(3):179–88.

    Article  PubMed  Google Scholar 

  55. Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatry. 2001;9(5):223–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Meadows Foundation & Semp Russ Professor of Child Psychiatry, Departments of Psychiatry and Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Joseph C. Blader

Authors
  1. Joseph C. Blader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Blader .

Editor information

Editors and Affiliations

  1. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Victor Fornari

  2. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Ida Dancyger

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blader, J.C. (2019). Nonadherence in Childhood Disorders: Attention-Deficit/Hyperactivity Disorder. In: Fornari, V., Dancyger, I. (eds) Psychiatric Nonadherence. Springer, Cham. https://doi.org/10.1007/978-3-030-12665-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-12665-0_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-12664-3

  • Online ISBN: 978-3-030-12665-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation